News
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Convatec Group PLC: Scrip Dividend - Calculation Price
Form 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
LivaNova to Announce First-Quarter 2023 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2023 results on Wednesday, May 3, 2023 at 1 p.m
Convatec Group PLC: Annual Report and Accounts 2022 and Notice of AGM
Convatec Group PLC: Director/PDMR Shareholding
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Convatec Group PLC: Director/PDMR Shareholding
LivaNova to Present at the Barclays Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Barclays
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Convatec Group PLC: Director/PDMR Shareholding
LivaNova Reports Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2022 and issued guidance for 2023.
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
LivaNova to Announce Fourth-Quarter and Full-Year 2022 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results on Wednesday, February
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through
Convatec Group PLC: Appointment of Joint Corporate Broker
Convatec Group PLC: Director/ PDMR Shareholding
LivaNova Announces Receipt of Close-Out of Warning Letter from U.S. Food and Drug Administration
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received a close-out letter from the U.S. Food and Drug Administration (FDA) for the
LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place
Convatec Group PLC: Total Voting Rights
Ergomed (ERGO): Two key management changes
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S